Pharmacological and molecular targets in the search for novel antipsychotics

Behavioural Pharmacology

Volumn 11, Issue 3-4, 2000, Pages 243-256

  Scatton, B ^a   Sanger, D J ^a  

^a SANOFI   (France)

Author keywords

Antipsychotics; Cannabinoid; Dopamine; Glutamate; Neurotensin; Serotonin; Sigma receptors

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA ADRENERGIC RECEPTOR; AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE AUTORECEPTOR; EPLIVANSERIN; FANANSERIN; FLUPHENAZINE; HALOPERIDOL; IDAZOXAN; ILOPERIDONE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; QUETIAPINE; RIMONABANT; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN RECEPTOR; SERTINDOLE; SIGMA OPIATE RECEPTOR; SULPIRIDE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; NONHUMAN; PREPULSE INHIBITION; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; STARTLE REFLEX;

EID: 0033936752     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200006000-00008     Document Type: Review

References (161)

1. Allen RM, Young SI (1978). Phencyclidine-induced psychosis. Am J Psychiatry 135:1081-1084.
2. 2 function. Neuroscience 91:607-620.
3. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH (1995). Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch Pharmacol 352:374-385.
4. Andreasen N, O'Leary D, Arndt S, Cizadlo T, Nopoulos P, Flaum M (1996). Neural substrates of frontal function in schizophrenia. In: Dopamine Disease States. Beninger RT, Palomo T, Archer T (editors). Madrid: Editorial Cym, pp. 523-536.
5. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62.
6. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
7. Ashby CR, Wang RY (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24:349-394.
8. 3 receptor antagonist (+)-S14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287:187-197.
9. Azzi M, Betancur C, Sillaber I, Spangel P, Rostene W, Berod A (1998). Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem 71:1158-1167.
10. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Rodgers RJ, Cooper SJ (editors). Chichester: Wiley, pp. 59-105.
11. Berman KF, Weinberger DR (1990). Prefrontal dopamine and defect symptoms in schizophrenia. In: Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Greden JF, Tandon R (editors). London: American Psychiatry Press, pp. 81-95.
12. Betancur C, Cabrera R, De Kloet E, Pelaprat D, Rostène W (1998). Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology 19:322-332.
13. Blin O (1999). A comparative review of new antipsychotics. Can J Psychiatry 44:235-244.
14. 3 knock-out and wild-type mice. Neuropharmacology 38:555-565.
15. 4 receptor antagonist does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283:1256-1263.
16. 4 receptor antagonist. Trends Pharmacol Sci 18:186-188.
17. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropharmacology 13:177-213.
18. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94.
19. Carlsson A (1978). Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164-173.
20. Carlsson M, Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
21. 3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol 7:105-109.
22. 1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102.
23. 3 dopamine antagonists using an ethologically based approach. Psychopharmacology 136:284-290.
24. Costa B, Vailati S, Colleoni M (1999). SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 10:327-331.
25. Coukell AJ, Spencer CM, Benfield P (1996). Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237-256.
26. Cudennec A, Fage D, Benavides J, Scatton B (1997). Effect of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res 768:257-265.
27. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology 20:491-505.
28. Darracq L, Blanc G, Glowinski J, Tassin JP (1998). Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 18:2729-2739.
29. Debonnel G, de Montigny C (1996). Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58:721-734.
30. Deutsch SI, Weizman A, Goldman ME, Morihisa JM (1988). The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol 11:105-119.
31. Dickson RA, Glazer WM (1999). Neuroleptic-induced hyperprolactinemia. Schizophr Res 35:S75-S86.
32. 3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther 287:51-57.
33. 2 receptor antagonist. Br J Pharmacol 105:27-36.
34. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 163:451-455.
35. Emrich HM, Leweke FM, Schneider U (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803-807.
36. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55(suppl B):67-69.
37. Feifel D, Roza TL, Robeck SL (1997). Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides 18:1457-1460.
38. Feifel D, Reza TL, Wustrow DJ, Davis MD (1999). Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288:710-713.
39. Freeman HL (1997). Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 12(suppl 2):S11-S18.
40. French ED (1997). Delta9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opiod receptors. Neurosci Lett 226:159-162.
41. Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A (1997). Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 132:82-88.
42. Fujikawa M, Nagashima M, Inoue T, Yamada K, Furukawa T (1996). Partial agonist effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 53:903-909.
43. Fulton B, Goa KL (1997). Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298.
44. Garreau M, Giroux C, L'Heritier C, Coupez M, Eich F, Morselli PL (1992). Pilot study on the effect of SL82.0715 in psychotic syndromes. Clin Neuropharmacol 15(suppl 1):699A-700A.
45. Gerlach J, Peacock L (1995). New antipsychotics: the present status. Int Clin Psychopharmacol 10(suppl 3):39-48.
46. Gessa G, Melis M, Muntoni A, Diana M (1998). Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39-43.
47. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994). BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40.
48. Goff DC, Tsai G, Manoach D, Coyle JT (1995). Dose finding trial of D-cycloserine added to neuroleptics for negative symptoms of schizophrenia. Am J Psychiatry 152:1213-1215.
49. Grant S, Fitton A (1994). Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48(2):253-273.
50. Grauer SM, Marquis KL (1999). Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 141:405-412.
51. Grunder G, Muller MJ, Andreas J, Heydari N, Wetzel H, Schlosser R, Schlegel S, Nickel O, Eissner D, Benkert O (1999a). Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology 146:81-86.
52. Grander G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999b). Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45:89-97.
53. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, Pelaprat D, Labbe-Jullié C, Mazella J, Soubrié P, Maffrand JP, Rostene W, Kitabgi P, Le Fur G (1993). Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 90:65-69.
54. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbé-Jullié C, Kitabgi P, Soubrié P, Le Fur G, Maffrand JP (1997). Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 280:802-812.
55. Guyon A, Assouly-Besse F, Biala G, Puech AJ, Thiébot MH (1993). Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology 110:460-466.
56. 3 receptor antagonist. CNS Drug Rev 4:42-53.
57. 4 receptors and their antagonists. Medicinal Res Rev 16:507-526.
58. 2 adrenoceptor blockade. Science 286:105-107.
59. Huber MT, Gotthardt U, Schreiber W, Kreig JC (1999). Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry 32:68-72.
60. Ichikawa J, Meltzer HY(1999). R(+)-8-OH-DPAT, a serotonin1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232.
61. Ishiguro H, Ohtsuki T, Tour M, Itokawa M, Aoki J, Shibuya H, Kurumaji A, Okubo Y, Iwawaki A, Ota K, Shimizu H, Hamaguchi H, Arinami T (1998). Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett 257:45-48.
62. Javitt DC, Zylberman I, Zukin S, Heresco-Levy U, Lindenmayer J (1994). Amelioration of negative symptoms of schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
63. Jeanjean AP, Laterre EC, Maloteaux JM (1997). Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia. Biol Psychiatry 41:1010-1019.
64. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:95-955.
65. Jentsch JD, Taylor JR, Redmond Jr DE, Elsworth JD, Youngren KD, Roth RH (1999). Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 142:78-84.
66. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, Rogers GA, Lynch G (1999). Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 289:392-397.
67. Josselyn SA, Miller R, Beninger RJ (1997). Behavioral effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21:531-558.
68. Joyce JN (1993). The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 112:516-534.
69. Kane J, Honigfield G, Singer J, Meltzer H (1988). The clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796.
70. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 124:35-39.
71. Kapur S, Remington G (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153(4):466-476.
72. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293.
73. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121:328-330.
74. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316.
75. Kasckow J, Nemeroff CB (1991). The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regul Pept 36:153-164.
76. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
77. 2 receptor antagonist activity. J Pharmacol Exp Ther 274:329-336.
78. Kinkead B, Binder EB, Nemeroff CB (1999). Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry 46:340-351.
79. Kinon BJ, Lieberman JA (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34.
80. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic patients with schizophrenia. Arch Gen Psychiatry 54:567-572.
81. 3 receptor binding affinities. Eur J Pharmacol 277:209-214.
82. Küfferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brücke T, Kasper S (1997). IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 133:323-328.
83. Langer SZ, Lehmann J (1988). Presynaptic receptors on catecholamine neurons. In: Catecholamines I. Trendelenburg U, Weiner N (editors). Berlin: Springer-Verlag, pp. 419-507.
84. Larson J, Quach CN, LeDuc BQ, Nguyen A, Rogers GA, Lynch G (1996). Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res 738:353-356.
85. Lamelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72.
86. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mialman RB (1999). Interactions of the novel antipsychotic oripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
87. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
88. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669.
89. 2 receptors. Psychopharmacology 112:540-554.
90. Liang X, Wang RY (1998). Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. Brain Res 807:208-213.
91. Liegeois JF, Bonaventure P, Delarge J, Damas J (1995). Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Neurosci Biobehav Rev 19:519-531.
92. Litmat RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D (1993). Idazoxan, an alpha Z agonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 13:264-267.
93. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976). The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
94. McAllister KH, Rey B (1999). Clozapine reversal of the deficits in coordinated movement induced by D2 receptor blockade does not depend upon antagonism of alpha2 adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 360:603-608.
95. Meltzer HY (1996). Preclinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 168(suppl 29):23-31.
96. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:1065-1155.
97. 2 pKi values. J Pharmacol Exp Ther 251:238-246.
98. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
99. Millan MJ, Gressier H, Brocco M (1997). The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7-R9.
100. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G (1998). S16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-γ loxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone) a novel, potential antipsychotic with marked serotonin (5HT) 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355.
101. Minabe Y, Matsuno K, Ashby CR (1999). Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 33:129-140.
102. Modell S, Naber D, Holzbach R (1996). Efficacy and safety of an opiate sigma-receptor antagonist (SL82.0715) in schizophrenia patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 29:63-66.
103. Montgomery AM, Grottick AJ, Herberg LJ (1999) Rapid recovery of self-stimulation responding from depression by clozapine is prevented by the alpha2-adreno-receptor agonist, clonidine. Behav Pharmacol 10:475-482.
104. 3 receptor. Bioorg Med Chem Lett 5:219-222.
105. Nishikawa T, Hashimoto S, Tanii Y, Umino A, Kashiwa A, Kumashiro S, Nishijima K, Oka T, Shirayama Y, Takahashi K (1994). Disturbed neurotransmission via the N-methyl-D-aspartate receptor and schizophrenia. In: The Biology of Schizophrenia. Moroji T, Yamamoto K (editors). Amsterdam: Elsevier, pp. 197-207.
106. Nutt DJ, Lalies MD, Lione LA, Hudson AL (1997). Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 11:163-168.
107. 1 receptors in schizophrenia revealed by PET. Nature 385:634-636.
108. Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M, Yamada S, Araki H, Otomo S (1994). NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 55:PL133-PL138.
109. Papp M, Wieronska J (2000). Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol in press.
110. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82.
111. Poncelet M, Santucci V, Paul R, Guendet C, Lavastre S, Guitard J, Steinberg R, Terranova JP, Breliere JC, Soubrie P, Le Fur G (1993). Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neurophamacology 32:605-615.
112. Poncelet M, Barnouin M-C, Breliere J-C, Le Fur G, Soubrie P (1999). Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144:144-150.
113. Prinssen EP, Ellenbroek BA, Cools AR (1994a). Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test. Br J Pharmacol 112:769-774.
114. Prinssen EP, Ellenbroek BA, Cools AR (1994b). Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170.
115. Prinssen EPM, Kleven MS, Koek W (1996). Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128:191-197.
116. Rabinowitz T, Frankenburg FR, Centorrino F, Kando J (1996). The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 40:1132-1134.
117. Rein W, Turjanski S (1997). Clinical update of amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12(suppl 2):S19-S28.
118. Remington G, Kapur S (2000). Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148:3-15.
119. 4 receptors in the action and development of antipsychotic drugs. Drugs 51:7-11.
120. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH (2000). Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47:22-28.
121. Richelson E (1999). Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiat 60(suppl 10):5-14.
122. Rigton GC, Norman MH, Cooper BR, Howard JL, Boncek VM, Faison WL, Nanry KP, Pollard GT (1996). 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology 15:231-242.
123. 2 receptor antagonist. J Pharmacol Exp Ther 262:759-767.
124. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere J-C, Le Fur G (1995). Biochemical and pharmacological characteristics of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947.
125. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Breliere J-C, Soubrie P, Le Fur G (1996). Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239-1247.
126. Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI (1990). An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 13:348-354.
127. Rostene W, Azzi M, Boudin H, Lepee I, Souaze F, Mendez-Ubach M, Betancz C, Gully D (1997). Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Ann NY Acad Sci 814:125-141.
128. Roth B, Craigo SC, Choudhary MS, Ulue A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1401-1410.
129. Sanchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, Perregaard J, Skarsfeldt T (1991). Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
130. Sanchez-Arroyas R, Guitart X (1999). Electrophysiological effects of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons. Eur J Pharmacol 379:31-37.
131. Santucci V, Gueudet C, Steinberg R, Le Fur G, Soubrié P (1997). Involvement of cortical neurotensin in the regulation of rat mesocorticolimbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse 28:370-380.
132. 3 receptor antagonist activates locomotion in rodents. J Pharmacol Exp Ther 275:1239-1246.
133. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H (1997). Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 12(suppl 2):S29-S36.
134. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
135. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
136. 3 receptor occupancy in vivo measured by radio-ligand binding. Soc Neurosci 23:abstract 270.11, p. 683.
137. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
138. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995). Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113.
139. Seeman P, Kapur S (1997). Clozapine occupies high levels of dopamine D2 receptors. Life Sci 60:PL207-216.
140. 2A receptors in antipsychotic and anticataleptic action. J Psychopharmacol 11:15-17.
141. Semba J, Watanabe A, Kito S, Toru M (1995). Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791.
142. Snyder SH, Largent BL (1989). Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry 1:7-15.
143. Snyder SH, Greenberg D, Yamamura HI (1974). Anti-schizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res 11:91-95.
144. 3) as a target for neuroleptics. Nature 347:146-151.
145. 2 receptor antagonist MDL100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691.
146. 1A receptor activation. Neuropsychopharmacology 21:622-631.
147. Strauss WH, Klieser E (1991). Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. Eur Neuropsychopharmacol 1:101-105.
148. Takahashi S, Sonehara K, Takagi K, Miwa T, Horikomi K, Mita N, Nagase H, Iczuka K, Sakai K (1999). Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology 145:295-302.
149. Tallman JF (1998). NGD 94-1: a specific dopamine-4-receptor antagonist. Adr Pharmacol 42:490-492.
150. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618-5621.
151. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Rodgers RJ, Cooper SJ (editors). Chichester: Wiley, pp. 159-194.
152. Toru M, Miura S, Kudo Y (1994). Clinical experience of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 10(suppl):122S.
153. 2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 156:419-425.
154. Wadenberg ML (1996). Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339.
155. Wadenberg ML, Ahlenius S (1991). Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53.
156. Walker JM, Matsumato RR, Bowen WD, Gans DL, Jones KD, Walker FO (1988). Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor side effects of antipsychotic drugs. Neurology 38:961-965.
157. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa BR, Rice KC (1990). Sigma receptors: biology and function. Pharmacol Rev 42:355-402.
158. Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994). An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114:31-38.
159. Willner P (1997). The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 12:297-308.
160. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 141:267-278.
161. 4 receptor agonist. Eur J Pharmacol 269:R1-R2.